Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes o
DURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the company’s le...